Antiretroviral therapy: State of the HAART

Antiviral Research

Volumn 45, Issue 1, 2000, Pages 1-7

  Vella, Stefano ^a   Palmisano, Lucia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 2' DEOXY 3' OXA 4' THIOCYTIDINE; 3 ETHYL 6 FLUORO 4 ISOPROPOXYCARBONYL 3,4 DIHYDRO QUINOXALIN 2(1H) ONE; ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CALANOLIDE A; CAPRAVIRINE; CD4 IMMUNOGLOBULIN G2; DELAVIRDINE; DMP 961 963; EFAVIRENZ; EMITRICITABINE; EMIVIRINE; ENFUVIRTIDE; FP 21399; INDINAVIR; IODENOSINE; L 756423; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033959183     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00068-6     Document Type: Review

References (20)

1. Autran B., Carcelain G., Li T.S. et al. Restoration of the immune system with anti-retroviral therapy. Immunol. Lett. 66:1999;207-211.
2. Baxter, J.D., Mayers, D.L., Wentworth, D.N., Neaton, J.D., Merrigan, T.C., 1999. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago IL.
3. Burger, D.W., Hugen, P.O.O.H., Prins, J.M., Van de Ende, M.E., Reiss, P., Lange, J.M.A. 1999. Pharmacokinetics of an Indinavir/Ritonavir 800/100mg BID regimen. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago IL.
4. Chun T.W., Engel D., Mizell S.B., Hallahan C.W., Fischette M., Park S. et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HlV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 6:1999;651-655.
5. Davey Jr R.T., Chaitt D.G., Albert J.M., Piscitelli S.C., Kovacs J.A., Walker R.E. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J. Infect. Dis. 179:1999;849-858.
6. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:1999;512-517.
7. Fischl, M., Greenber, S., Clumeck, N., Peters, B., Rubio, R., Gould, J. et al., 1999. Ziagen (Abacavir, ABC, 1592) combined with 3TC and ZDV is effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy naïve subjects (CNM3003). Sixth Conference on Retroviruses and Opportunistic Infections, Chicago IL
8. Haviir, D., Hellmann, N., Petropoulos, C., Whitcomb, J., Collier, A., Hirsch, M., Tebas, P., Richman, D., 1999. Viral rebound in the presence of indinavir without protease inhibitors resistance. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago IL.
9. Lisziewicz J., Rosenberg E., Lieberman J., Jessen H., Lopalco L., Siliciano R. Control of HIV despite the discontinuation of antiretroviral therapy. New Eng. J. Med. 340:1999;1683-1684.
10. Montaner J.S. Induction/maintenance treatment regimens for HIV. J. Am. Med. Assoc. 281:1999;1680-1682.
11. Montaner J.S., Hogg R., Raboud J., Harrigan R., O'Shaughnessy M. Antiretroviral treatment in 1998. Lancet. 352:1998;1919-1922.
12. Palella Jr F.J.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New Eng. J. Med. 338:1998;853-860.
13. Perrin L., Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science. 280:1998;1871-1873.
14. Pezzotti P., Napoli P.A., Accini S., Boros S., Urciuoli R., Lazeri V. et al. Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group. AIDS. 13:1999;249-255.
15. Pitcher C.J., Quittner C., Peterson D.M., Connors M., Koup R.A., Maino V.C. et al. HIV-1-specific CD4+T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5:1999;518-525.
16. Raboud J.M., Montaner J.S., Conway B., Rae S., Reiss P., Vella S. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 12:1998;1619-1624.
17. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A. et al. Vigorous HlV-1-specific CD4+ T cell responses associated with control of viremia. Science. 278:1997;1447-1450.
18. Sendi P.P., Bucher H.C., Craig B.A., Pfluger D., Battegay M. Estimating AIDS free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss Cohort study. J. Acquir. Imm. Defic. Syndr. Hum. Retrovirol. 20:1999;376-381.
19. Tashima, K., Staszewski, S., Stryker, R., Johnson, P., Nelson, M., Morales-Ramirez, J., 1999. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago IL.
20. Valentine, F.T., De Gruttola, V. and the Remune 816 Study Team, 1999. Effects of HMRT compared to HMRT plus an inactivated HIV immunogen after 32 weeks. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago IL.